Thermo Fisher Scientific (TMO) 10-Q 30 Oct 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 26, 2020shares
Entity Listings [Line Items]
Entity Central Index Key	0000097745
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 26, 2020
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	396,335,191
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
Floating Rate Notes due 2020
Entity Listings [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2020
Trading Symbol	TMO /20A
Security Exchange Name	NYSE
2.150% Notes due 2022
Entity Listings [Line Items]
Title of 12(b) Security	2.150% Notes due 2022
Trading Symbol	TMO 22A
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 7,540	$ 2,399
Accounts receivable, less allowances of $117 and $102	5,186	4,349
Inventories	3,829	3,370
Contract assets, net	697	603
Other current assets	982	1,172
Total current assets	18,234	11,893
Property, Plant and Equipment, Net	5,180	4,749
Acquisition-related Intangible Assets, Net	12,870	14,014
Other Assets	1,995	2,011
Goodwill	25,782	25,714
Total Assets	64,061	58,381
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	2	676
Accounts payable	1,703	1,920
Accrued payroll and employee benefits	1,538	1,010
Contract liabilities	1,047	916
Other accrued expenses	1,938	1,675
Total current liabilities	6,228	6,197
Deferred Income Taxes	1,528	2,192
Other Long-term Liabilities	3,390	3,241
Long-term Obligations	21,091	17,076
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 436,746,267 and 434,416,804 shares issued	437	434
Capital in excess of par value	15,467	15,064
Retained earnings	25,705	22,092
Treasury stock at cost, 40,411,076 and 35,676,421 shares	(6,815)	(5,236)
Accumulated other comprehensive items	(2,970)	(2,679)
Total shareholders' equity	31,824	29,675
Total Liabilities and Shareholders' Equity	$ 64,061	$ 58,381

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 117	$ 102
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	436,746,267	434,416,804
Treasury Stock at Cost (in shares)	40,411,076	35,676,421

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Revenues
Revenues	$ 8,521	$ 6,272	$ 21,668	$ 18,713
Costs and Operating Expenses:
Selling, general and administrative expenses	1,592	1,539	4,853	4,632
Research and development expenses	296	247	805	741
Restructuring and other costs (income), net	17	31	67	(442)
Total costs and operating expenses	6,095	5,326	16,945	15,351
Operating Income	2,426	946	4,723	3,362
Interest Income	9	52	53	179
Interest Expense	(144)	(164)	(407)	(534)
Other (Expense) Income, Net	(39)	(12)	(36)	25
Income Before Income Taxes	2,252	822	4,333	3,032
Provision for Income Taxes	(319)	(62)	(456)	(338)
Net Income	$ 1,933	$ 760	$ 3,877	$ 2,694
Earnings per Share
Basic (in dollars per share)	$ 4.88	$ 1.89	$ 9.79	$ 6.73
Diluted (in dollars per share)	$ 4.84	$ 1.88	$ 9.71	$ 6.68
Weighted Average Shares
Basic (in shares)	396	401	396	400
Diluted (in shares)	399	404	399	403
Product [Member]
Revenues
Revenues	$ 6,782	$ 4,798	$ 16,662	$ 14,345
Costs and Operating Expenses:
Cost of revenues	3,001	2,471	7,732	7,363
Service [Member]
Revenues
Revenues	1,739	1,474	5,006	4,368
Costs and Operating Expenses:
Cost of revenues	$ 1,189	$ 1,038	$ 3,488	$ 3,057

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Comprehensive Income
Net income	$ 1,933	$ 760	$ 3,877	$ 2,694
Currency translation adjustment:
Currency translation adjustment (net of tax (benefit) provision of $(76), $77, $(71) and $92)	10	(91)	(244)	(222)
Reclassification adjustment for losses included in net income	0	30	0	30
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $12, $20 and $12)	0	(38)	(65)	(38)
Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1, $4 and $3)	6	2	10	7
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax benefit (provision) of $1, $(2), $2 and $2)	(4)	2	(5)	(9)
Amortization of net loss included in net periodic pension cost (net of tax benefit of $1, $0, $4 and $2)	7	3	13	8
Total other comprehensive items	19	(92)	(291)	(224)
Comprehensive Income	$ 1,952	$ 668	$ 3,586	$ 2,470

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ (76)	$ 77	$ (71)	$ 92
Tax benefit on unrealized holding losses on hedging instruments arising during the period	0	12	20	12
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	2	1	4	3
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	1	(2)	2	2
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 1	$ 0	$ 4	$ 2

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Operating Activities
Net income	$ 3,877	$ 2,694
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	467	416
Amortization of acquisition-related intangible assets	1,256	1,285
Change in deferred income taxes	(496)	(356)
Gain on sales of businesses	0	(486)
Stock-based compensation	145	138
Other non-cash expenses, net	209	123
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable	(858)	(321)
Inventories	(427)	(449)
Accounts payable	(220)	70
Contributions to retirement plans	(45)	(40)
Other	1,042	(14)
Net cash provided by operating activities	4,950	3,060
Investing Activities
Acquisitions, net of cash acquired	(3)	(1,687)
Proceeds from sale of business, net of cash divested	0	1,128
Purchase of property, plant and equipment	(888)	(637)
Proceeds from sale of property, plant and equipment	7	18
Other investing activities, net	0	30
Net cash used in investing activities	(884)	(1,148)
Financing Activities
Net proceeds from issuance of debt	3,464	0
Repayment of debt	(712)	(1,702)
Proceeds from issuance of commercial paper	383	2,581
Repayments of commercial paper	(387)	(2,578)
Purchases of company common stock	(1,500)	(750)
Dividends paid	(250)	(221)
Net proceeds from issuance of company common stock under employee stock plans	156	115
Other financing activities, net	(146)	(49)
Net cash provided by (used in) financing activities	1,008	(2,604)
Exchange Rate Effect on Cash	74	(120)
Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	5,148	(812)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	2,422	2,117
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 7,570	$ 1,305

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2018			432				29
Balance at Dec. 31, 2018	$ 27,586	$ 4	$ 432	$ 14,621	$ 18,696	$ 4	$ (3,665)	$ (2,498)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			2				1
Issuance of shares under employees' and directors' stock plans	136		$ 2	205			$ (71)
Stock-based compensation	138			138
Purchases of company common stock (in shares)							3
Purchases of company common stock	(750)						$ (750)
Dividends declared	(229)				(229)
Net income	2,694				2,694
Other comprehensive items	(224)							(224)
Balance (in shares) at Sep. 28, 2019			434				33
Balance at Sep. 28, 2019	29,355		$ 434	14,964	21,165		$ (4,486)	(2,722)
Balance (in shares) at Jun. 29, 2019			433				33
Balance at Jun. 29, 2019	28,729		$ 433	14,887	20,482		$ (4,443)	(2,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1
Issuance of shares under employees' and directors' stock plans	(7)		$ 1	35			$ (43)
Stock-based compensation	42			42
Dividends declared	(77)				(77)
Net income	760				760
Other comprehensive items	(92)							(92)
Balance (in shares) at Sep. 28, 2019			434				33
Balance at Sep. 28, 2019	29,355		$ 434	14,964	21,165		$ (4,486)	(2,722)
Balance (in shares) at Dec. 31, 2019			434				36
Balance at Dec. 31, 2019	29,675	$ (1)	$ 434	15,064	22,092	$ (1)	$ (5,236)	(2,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			3				0
Issuance of shares under employees' and directors' stock plans	182		$ 3	258			$ (79)
Stock-based compensation	145			145
Purchases of company common stock (in shares)							4
Purchases of company common stock	(1,500)						$ (1,500)
Dividends declared	(263)				(263)
Net income	3,877				3,877
Other comprehensive items	(291)							(291)
Balance (in shares) at Sep. 26, 2020			437				40
Balance at Sep. 26, 2020	31,824		$ 437	15,467	25,705		$ (6,815)	(2,970)
Balance (in shares) at Jun. 27, 2020			436				40
Balance at Jun. 27, 2020	29,875		$ 436	15,334	23,860		$ (6,766)	(2,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				0
Issuance of shares under employees' and directors' stock plans	33		$ 1	81			$ (49)
Stock-based compensation	52			52
Dividends declared	(88)				(88)
Net income	1,933				1,933
Other comprehensive items	19							19
Balance (in shares) at Sep. 26, 2020			437				40
Balance at Sep. 26, 2020	$ 31,824		$ 437	$ 15,467	$ 25,705		$ (6,815)	$ (2,970)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.22	$ 0.19	$ 0.66	$ 0.57

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 26, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at September 26, 2020, the results of operations for the three- and nine-month periods ended September 26, 2020 and September 28, 2019, and the cash flows for the nine-month periods ended September 26, 2020 and September 28, 2019. Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 31, 2019, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2019 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2019 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months ended September 26, 2020. Contract-related Balances Accounts receivable include amounts that have been billed and are currently due from customers. They are recorded at the invoiced amount and do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers. The changes in the allowance for doubtful accounts are as follows: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Balance at Beginning of Year $ 102 $ 117 Cumulative effect of accounting change 1 — Provision charged to expense 39 19 Accounts written off (25) (26) Acquisitions, currency translation and other — (4) Balance at End of Period $ 117 $ 106 Contract assets include revenues recognized in advance of billings and are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract. Contract asset and liability balances are as follows: September 26, December 31, (In millions) 2020 2019 Current Contract Assets, Net $ 697 $ 603 Noncurrent Contract Assets, Net 11 17 Current Contract Liabilities 1,047 916 Noncurrent Contract Liabilities 674 594 In the three and nine months ended September 26, 2020, the company recognized revenues of $142 million and $773 million, respectively, that were included in the contract liabilities balance at December 31, 2019. Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Balance at Beginning of Year $ 93 $ 92 Provision charged to expense 74 80 Usage (76) (83) Adjustments to previously provided warranties, net (2) (1) Currency translation — (2) Balance at End of Period $ 89 $ 86 Inventories The components of inventories are as follows: September 26, December 31, (In millions) 2020 2019 Raw Materials $ 1,247 $ 971 Work in Process 558 517 Finished Goods 2,024 1,882 Inventories $ 3,829 $ 3,370 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic have and will continue to materially adversely affect certain of the company’s businesses, particularly in the Analytical Instruments segment and, to a lesser extent, in some businesses within the other three segments, through at least the fourth quarter of 2020. The extent and duration of such impacts are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company expects to adopt this guidance when it is effective in 2021 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures.

Acquisitions and Dispositions

Acquisitions and Dispositions	9 Months Ended
	Sep. 26, 2020
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions and Dispositions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. Terminated Acquisition As previously announced, on March 3, 2020, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of QIAGEN N.V. (“QIAGEN”). Following a determination that the number of shares tendered by QIAGEN shareholders did not meet the minimum amount required for the transaction to proceed, on August 13, 2020, the company delivered to QIAGEN a written notice terminating the purchase agreement in accordance with the terms of the agreement. In connection with the termination, QIAGEN paid to the company an expense reimbursement payment of $95 million in cash which has been recorded as a reduction of selling, general and administrative expenses. Disposition

Revenue

Revenue	9 Months Ended
	Sep. 26, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenues Disaggregated Revenues Revenues by type are as follows: Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues Consumables 4,956 3,228 $ 12,214 $ 9,726 Instruments 1,826 1,570 4,448 4,619 Services 1,739 1,474 5,006 4,368 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 Revenues by geographic region are as follows: Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues (a) North America $ 4,587 $ 3,220 $ 11,418 $ 9,509 Europe 2,032 1,514 5,464 4,569 Asia-Pacific 1,607 1,349 4,054 4,080 Other regions 295 189 732 555 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 (a) Revenues are attributed to regions based on customer location. Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 26, 2020 was $11.16 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 72% of which is expected to occur within the next twelve months.

Business Segment and Geographic

Business Segment and Geographical Information	9 Months Ended
	Sep. 26, 2020
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information Business Segment Information Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues Life Sciences Solutions $ 3,424 $ 1,701 $ 7,800 $ 5,018 Analytical Instruments 1,336 1,358 3,488 4,004 Specialty Diagnostics 1,430 879 3,376 2,779 Laboratory Products and Services 3,112 2,619 8,629 7,765 Eliminations (781) (285) (1,625) (853) Consolidated revenues 8,521 6,272 21,668 18,713 Segment Income (a) Life Sciences Solutions 1,879 586 3,788 1,756 Analytical Instruments 171 311 477 879 Specialty Diagnostics 398 223 848 707 Laboratory Products and Services 355 303 931 933 Subtotal reportable segments (a) 2,803 1,423 6,044 4,275 Cost of revenues charges, net (1) (5) (5) (16) Selling, general and administrative credits (charges), net 55 (7) 7 (54) Restructuring and other (costs) income, net (17) (31) (67) 442 Amortization of acquisition-related intangible assets (414) (434) (1,256) (1,285) Consolidated operating income 2,426 946 4,723 3,362 Interest income (b) 9 52 53 179 Interest expense (b) (144) (164) (407) (534) Other (expense) income, net (b) (39) (12) (36) 25 Income before income taxes $ 2,252 $ 822 $ 4,333 $ 3,032 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments. Geographical Information Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues (c) United States $ 4,428 $ 3,096 $ 10,981 $ 9,117 China 828 694 1,886 2,072 Other 3,265 2,482 8,801 7,524 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 (c) Revenues are attributed to countries based on customer location.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 26, 2020
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 5. Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 910 $ 637 Increases (Decreases) Resulting From: Foreign rate differential (132) (172) Foreign exchange loss on inter-company debt refinancing — (62) Income tax credits (333) (242) Global intangible low-taxed income 210 160 Foreign-derived intangible income (53) (68) Excess tax benefits from stock options and restricted stock units (94) (68) Basis difference on disposal of business — 72 Other, net (52) 81 Provision for Income Taxes $ 456 $ 338 The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In the second quarter of 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S. income tax expense. Unrecognized Tax Benefits As of September 26, 2020, the company had $1.51 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2020 Balance at Beginning of Year $ 1,552 Additions for tax positions of current year 6 Reductions for tax positions of prior years (38) Settlements (7) Balance at End of Period $ 1,513

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 26, 2020
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 6. Earnings per Share Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions except per share amounts) 2020 2019 2020 2019 Net Income $ 1,933 $ 760 $ 3,877 $ 2,694 Basic Weighted Average Shares 396 401 396 400 Plus Effect of: Stock options and restricted units 3 3 3 3 Diluted Weighted Average Shares 399 404 399 403 Basic Earnings per Share $ 4.88 $ 1.89 $ 9.79 $ 6.73 Diluted Earnings per Share $ 4.84 $ 1.88 $ 9.71 $ 6.68 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares — 1 1 1

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Sep. 26, 2020
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 7. Debt and Other Financing Arrangements Effective Interest Rate at September 26, September 26, December 31, (Dollars in millions) 2020 2020 2019 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) $ — $ 673 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 582 561 3.00% 7-Year Senior Notes, Due 4/15/2023 1.73 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,163 1,121 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 930 897 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 744 717 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 814 785 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 582 561 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 698 — 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 930 897 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 698 673 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 814 785 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,047 1,009 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 698 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 814 785 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,047 1,009 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,163 1,121 Other 8 16 Total Borrowings at Par Value 21,282 17,960 Fair Value Hedge Accounting Adjustments 30 (13) Unamortized Discount, Net (101) (94) Unamortized Debt Issuance Costs (118) (101) Total Borrowings at Carrying Value 21,093 17,752 Less: Short-term Obligations and Current Maturities 2 676 Long-term Obligations $ 21,091 $ 17,076 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 10 for fair value information pertaining to the company’s long-term obligations. In connection with the termination of the agreement to acquire QIAGEN (Note 2), the company terminated the bridge and term loan commitments which had been available to fund the acquisition. The company had a cash outlay of $51 million in 2020 associated with obtaining the bridge and term loan commitments included in other financing activities, net, in the accompanying statement of cash flows. In 2020, other expense, net includes $81 million of costs for the terminated QIAGEN acquisition, primarily for loan commitment fees and entering into hedging contracts. Credit Facilities The company has a revolving credit facility, as amended, (the Facility) with a bank group that provides for up to $2.5 billion of unsecured multi-currency revolving credit. The Facility expires in July 2022. The revolving credit agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Leverage Ratio (net debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 5.0:1.0, with such ratio stepping down to 4.0 to 1.0 for the two consecutive fiscal quarters starting on the last day of the first fiscal quarter of 2022 and then stepping down to 3.5 to 1.0 for each fiscal quarter ending thereafter. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter. As of September 26, 2020, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $66 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of September 26, 2020, there were no outstanding borrowings under these programs. Senior Notes Interest is payable annually on the euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. Interest Rate Swap Arrangements and related Cross-currency Interest Rate Swap Arrangements The company has entered into LIBOR-based interest rate swap arrangements with various banks. The aggregate amounts of the swaps are equal to the principal amount of the notes and the payment dates of the swaps coincide with the interest payment dates of the note. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 10 for additional information on the interest rate swap arrangements and related cross-currency interest rate swap arrangements. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at September 26, 2020: Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate September 26, Receive Rate 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 1.9164 % 3.00 % (a) The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of September 26, 2020 from 1.92% to a weighted average of 1.13%. The company has entered into $900 million notional value of cross-currency interest rate swaps, which effectively convert a portion of the semi-annual payments related to the variable rate, U.S. dollar denominated, LIBOR-based interest rate swaps to payments on variable rate, euro denominated, EURIBOR-based cross-currency interest rate swaps.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 26, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 8. Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At September 26, 2020, the company’s total environmental liability was approximately $70 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2019 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Intellectual Property Matters On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies, a subsidiary of the company, in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product “supply centers” installed at customer sites. Plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On September 30, 2020, this matter was settled by payment of a nominal amount by the company. Strategic Partnership and Long-term Lease In May 2020, the company entered a strategic partnership with CSL Limited (CSL). Through a long-term lease agreement with CSL, the company will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in mid-2021, to perform pharma services for CSL with capacity to serve other customers as well. The company made an initial lease payment of $50 million in the second quarter of 2020 (included within other assets in the accompanying balance sheet) and expects to make additional fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent on the extent of revenues from customers of the facility other than CSL. Loss on Supply Agreement The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in the third quarter of 2020 related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company has developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.

Comprehensive Income

Comprehensive Income	9 Months Ended
	Sep. 26, 2020
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 9. Comprehensive Income Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2019 $ (2,320) $ (71) $ (288) $ (2,679) Other comprehensive items before reclassifications (244) (65) (5) (314) Amounts reclassified from accumulated other comprehensive items — 10 13 23 Net other comprehensive items (244) (55) 8 (291) Balance at September 26, 2020 $ (2,564) $ (126) $ (280) $ (2,970)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	9 Months Ended
	Sep. 26, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 10. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of September 26, 2020 and December 31, 2019: September 26, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 6,021 $ 6,021 $ — $ — Investments in common stock, mutual funds and other similar instruments 22 22 — — Warrants 9 — 9 — Insurance contracts 140 — 140 — Derivative contracts 49 — 49 — Total Assets $ 6,241 $ 6,043 $ 198 $ — Liabilities Derivative contracts $ 68 $ — $ 68 $ — Contingent consideration 44 — — 44 Total Liabilities $ 112 $ — $ 68 $ 44 December 31, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,280 $ 1,280 $ — $ — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 131 — 131 — Derivative contracts 37 — 37 — Total Assets $ 1,473 $ 1,299 $ 174 $ — Liabilities Derivative contracts $ 24 $ — $ 24 $ — Contingent consideration 55 — — 55 Total Liabilities $ 79 $ — $ 24 $ 55 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Contingent Consideration Beginning Balance $ 53 $ 58 $ 55 $ 37 Acquisitions (including assumed balances) — — — 24 Payments (1) (3) (3) (3) Change in fair value included in earnings (8) — (8) (3) Ending Balance $ 44 $ 55 $ 44 $ 55 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. September 26, December 31, (In millions) 2020 2019 Notional Amount Interest rate swaps - fair value hedges (described in Note 7) $ 1,000 $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Cross-currency interest rate swaps 1,000 — Currency exchange contracts 3,893 2,846 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities September 26, December 31, September 26, December 31, (In millions) 2020 2019 2020 2019 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 30 $ — $ — $ 13 Cross-currency interest rate swaps (a) 9 33 5 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 10 4 54 11 Cross-currency interest rate swaps (a) — — 9 — Total Derivatives $ 49 $ 37 $ 68 $ 24 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the consolidated balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability September 26, December 31, September 26, December 31, (In millions) 2020 2019 2020 2019 Long-term Obligations $ 1,024 $ 980 $ 30 $ (13) Gain (Loss) Recognized Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ — $ (14) $ (43) $ (95) Derivatives designated as hedging instruments - included in other expense, net — 15 43 98 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (50) (85) (50) Amount reclassified from accumulated other comprehensive items to other expense, net (8) (3) (14) (10) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items (295) 261 (276) 320 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items (30) 72 (30) 79 Included in other expense, net 2 13 9 41 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues (2) 1 (2) — Included in other expense, net 51 43 7 49 Cross-currency interest rate swaps Included in other expense, net 1 — (9) — Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company also uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and certain of its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. The company also had $1 billion notional value of cross currency swaps which the company terminated in October 2020. These swaps were entered into in anticipation of using U.S. dollars to partially finance the euro purchase price of the terminated QIAGEN acquisition (Note 2). Gains and losses associated with these swaps were recorded in other expense, net. See Note 1 to the consolidated financial statements for 2019 included in the company's Annual Report on Form 10-K and Note 7 herein for additional information on the company's risk management objectives and strategies. Cash Flow Hedge Arrangements In March 2020, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of future debt offerings. Based on the company's conclusion that the debt offerings are probable, the swaps hedge the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. One of these hedges was terminated in March 2020, in connection with the debt offering completed in that month. The remaining hedges were terminated in July 2020. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million in 2020 associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash flows. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt obligations are as follows: September 26, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 21,085 $ 23,415 $ 17,736 $ 18,650 Other 8 8 16 16 $ 21,093 $ 23,423 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 26, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 11. Supplemental Cash Flow Information Nine Months Ended September 26, September 28, (In millions) 2020 2019 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 88 $ 77 Issuance of stock upon vesting of restricted stock units 209 179 Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: September 26, December 31, (In millions) 2020 2019 Cash and Cash Equivalents $ 7,540 $ 2,399 Restricted Cash Included in Other Current Assets 29 21 Restricted Cash Included in Other Assets 1 2 Cash, Cash Equivalents and Restricted Cash $ 7,570 $ 2,422 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs (

Restructuring and Other Costs (Income), Net	9 Months Ended
	Sep. 26, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 12. Restructuring and Other Costs (Income), Net In the first nine months of 2020 the company recorded transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and, to a lesser extent, impairment of acquired technology in development and non-cash charges for writedowns of fixed assets to estimated disposal value in connection with the consolidation of commercial production operations in the U.S. In the first nine months of 2020, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce. As of October 30, 2020, the company has identified restructuring actions that will result in additional charges of approximately $45 million, primarily in 2020 and 2021, and expects to identify additional actions during 2020 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. During the third quarter of 2020, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (8) $ 10 $ 2 Analytical Instruments — — 3 3 Specialty Diagnostics — (50) 2 (48) Laboratory Products and Services 1 — 1 2 Corporate — 3 1 4 $ 1 $ (55) $ 17 $ (37) During the first nine months of 2020, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (8) $ 11 $ 3 Analytical Instruments — — 22 22 Specialty Diagnostics — (4) 8 4 Laboratory Products and Services 5 2 20 27 Corporate — 3 6 9 $ 5 $ (7) $ 67 $ 65 The principal components of net restructuring and other costs (income) by segment are as follows: Life Sciences Solutions In the first nine months of 2020, the Life Sciences Solutions segment recorded $3 million of net restructuring and other charges. The segment recorded $11 million of restructuring and other costs, net, primarily charges for impairment of acquired technology in development. The segment also recorded $8 million of credits to selling, general, and administrative expense for changes in estimates of contingent acquisition consideration. Analytical Instruments In the first nine months of 2020, the Analytical Instruments segment recorded $22 million of net restructuring and other charges, primarily for employee severance associated with headcount reductions in Europe, China, and the U.S., and, to a lesser extent, abandoned facility costs. Specialty Diagnostics In the first nine months of 2020, the Specialty Diagnostics segment recorded $4 million of net restructuring and other charges, principally charges for third-party transaction costs (including reimbursement thereof) for a terminated acquisition. Laboratory Products and Services In the first nine months of 2020, the Laboratory Products and Services segment recorded $27 million of net restructuring and other charges, primarily for employee severance at businesses streamlining operations and for writedowns of fixed assets to estimated disposal value in connection with the consolidation of commercial production operations in the U.S. Corporate In the first nine months of 2020, the company recorded $9 million of net restructuring and other costs for severance at its corporate operations and, to a lesser extent, charges to selling, general, and administrative expense for product liability litigation. The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2019 $ 34 Net restructuring charges incurred in 2020 (b) 43 Payments (46) Currency translation 1 Balance at September 26, 2020 $ 32 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Excludes $24 million of charges for impairment of acquired technology in development, fixed asset writedowns and costs associated with environmental remediation at abandoned / previously owned facilities. The company expects to pay accrued restructuring costs primarily through 2021.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 26, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts receivable include amounts that have been billed and are currently due from customers. They are recorded at the invoiced amount and do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company expects to adopt this guidance when it is effective in 2021 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures.
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Acquisitions and Dispositions (

Acquisitions and Dispositions (Policies)	9 Months Ended
	Sep. 26, 2020
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 26, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	The changes in the allowance for doubtful accounts are as follows: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Balance at Beginning of Year $ 102 $ 117 Cumulative effect of accounting change 1 — Provision charged to expense 39 19 Accounts written off (25) (26) Acquisitions, currency translation and other — (4) Balance at End of Period $ 117 $ 106
Contract with Customer, Asset and Liability [Table Text Block]	Contract asset and liability balances are as follows: September 26, December 31, (In millions) 2020 2019 Current Contract Assets, Net $ 697 $ 603 Noncurrent Contract Assets, Net 11 17 Current Contract Liabilities 1,047 916 Noncurrent Contract Liabilities 674 594
Warranty Obligations [Table Text Block]	Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Balance at Beginning of Year $ 93 $ 92 Provision charged to expense 74 80 Usage (76) (83) Adjustments to previously provided warranties, net (2) (1) Currency translation — (2) Balance at End of Period $ 89 $ 86
Inventories [Table Text Block]	Inventories The components of inventories are as follows: September 26, December 31, (In millions) 2020 2019 Raw Materials $ 1,247 $ 971 Work in Process 558 517 Finished Goods 2,024 1,882 Inventories $ 3,829 $ 3,370

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 26, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenues Revenues by type are as follows: Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues Consumables 4,956 3,228 $ 12,214 $ 9,726 Instruments 1,826 1,570 4,448 4,619 Services 1,739 1,474 5,006 4,368 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 Revenues by geographic region are as follows: Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues (a) North America $ 4,587 $ 3,220 $ 11,418 $ 9,509 Europe 2,032 1,514 5,464 4,569 Asia-Pacific 1,607 1,349 4,054 4,080 Other regions 295 189 732 555 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 (a) Revenues are attributed to regions based on customer location.

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 26, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues Life Sciences Solutions $ 3,424 $ 1,701 $ 7,800 $ 5,018 Analytical Instruments 1,336 1,358 3,488 4,004 Specialty Diagnostics 1,430 879 3,376 2,779 Laboratory Products and Services 3,112 2,619 8,629 7,765 Eliminations (781) (285) (1,625) (853) Consolidated revenues 8,521 6,272 21,668 18,713 Segment Income (a) Life Sciences Solutions 1,879 586 3,788 1,756 Analytical Instruments 171 311 477 879 Specialty Diagnostics 398 223 848 707 Laboratory Products and Services 355 303 931 933 Subtotal reportable segments (a) 2,803 1,423 6,044 4,275 Cost of revenues charges, net (1) (5) (5) (16) Selling, general and administrative credits (charges), net 55 (7) 7 (54) Restructuring and other (costs) income, net (17) (31) (67) 442 Amortization of acquisition-related intangible assets (414) (434) (1,256) (1,285) Consolidated operating income 2,426 946 4,723 3,362 Interest income (b) 9 52 53 179 Interest expense (b) (144) (164) (407) (534) Other (expense) income, net (b) (39) (12) (36) 25 Income before income taxes $ 2,252 $ 822 $ 4,333 $ 3,032 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues Life Sciences Solutions $ 3,424 $ 1,701 $ 7,800 $ 5,018 Analytical Instruments 1,336 1,358 3,488 4,004 Specialty Diagnostics 1,430 879 3,376 2,779 Laboratory Products and Services 3,112 2,619 8,629 7,765 Eliminations (781) (285) (1,625) (853) Consolidated revenues 8,521 6,272 21,668 18,713 Segment Income (a) Life Sciences Solutions 1,879 586 3,788 1,756 Analytical Instruments 171 311 477 879 Specialty Diagnostics 398 223 848 707 Laboratory Products and Services 355 303 931 933 Subtotal reportable segments (a) 2,803 1,423 6,044 4,275 Cost of revenues charges, net (1) (5) (5) (16) Selling, general and administrative credits (charges), net 55 (7) 7 (54) Restructuring and other (costs) income, net (17) (31) (67) 442 Amortization of acquisition-related intangible assets (414) (434) (1,256) (1,285) Consolidated operating income 2,426 946 4,723 3,362 Interest income (b) 9 52 53 179 Interest expense (b) (144) (164) (407) (534) Other (expense) income, net (b) (39) (12) (36) 25 Income before income taxes $ 2,252 $ 822 $ 4,333 $ 3,032 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Revenues (c) United States $ 4,428 $ 3,096 $ 10,981 $ 9,117 China 828 694 1,886 2,072 Other 3,265 2,482 8,801 7,524 Consolidated revenues $ 8,521 $ 6,272 $ 21,668 $ 18,713 (c) Revenues are attributed to countries based on customer location.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 26, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended September 26, September 28, (In millions) 2020 2019 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 910 $ 637 Increases (Decreases) Resulting From: Foreign rate differential (132) (172) Foreign exchange loss on inter-company debt refinancing — (62) Income tax credits (333) (242) Global intangible low-taxed income 210 160 Foreign-derived intangible income (53) (68) Excess tax benefits from stock options and restricted stock units (94) (68) Basis difference on disposal of business — 72 Other, net (52) 81 Provision for Income Taxes $ 456 $ 338
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2020 Balance at Beginning of Year $ 1,552 Additions for tax positions of current year 6 Reductions for tax positions of prior years (38) Settlements (7) Balance at End of Period $ 1,513

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 26, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions except per share amounts) 2020 2019 2020 2019 Net Income $ 1,933 $ 760 $ 3,877 $ 2,694 Basic Weighted Average Shares 396 401 396 400 Plus Effect of: Stock options and restricted units 3 3 3 3 Diluted Weighted Average Shares 399 404 399 403 Basic Earnings per Share $ 4.88 $ 1.89 $ 9.79 $ 6.73 Diluted Earnings per Share $ 4.84 $ 1.88 $ 9.71 $ 6.68 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares — 1 1 1

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Sep. 26, 2020
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at September 26, September 26, December 31, (Dollars in millions) 2020 2020 2019 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) $ — $ 673 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 582 561 3.00% 7-Year Senior Notes, Due 4/15/2023 1.73 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,163 1,121 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 930 897 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 744 717 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 814 785 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 582 561 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 698 — 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 930 897 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 698 673 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 814 785 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,047 1,009 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 698 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 814 785 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,047 1,009 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,163 1,121 Other 8 16 Total Borrowings at Par Value 21,282 17,960 Fair Value Hedge Accounting Adjustments 30 (13) Unamortized Discount, Net (101) (94) Unamortized Debt Issuance Costs (118) (101) Total Borrowings at Carrying Value 21,093 17,752 Less: Short-term Obligations and Current Maturities 2 676 Long-term Obligations $ 21,091 $ 17,076
Schedule of Derivative Instruments [Table Text Block]	Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate September 26, Receive Rate 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 1.9164 % 3.00 % (a) The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of September 26, 2020 from 1.92% to a weighted average of 1.13%.

Comprehensive Income (Tables)

Comprehensive Income (Tables)	9 Months Ended
	Sep. 26, 2020
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2019 $ (2,320) $ (71) $ (288) $ (2,679) Other comprehensive items before reclassifications (244) (65) (5) (314) Amounts reclassified from accumulated other comprehensive items — 10 13 23 Net other comprehensive items (244) (55) 8 (291) Balance at September 26, 2020 $ (2,564) $ (126) $ (280) $ (2,970)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 26, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	September 26, 2020 and December 31, 2019: September 26, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 6,021 $ 6,021 $ — $ — Investments in common stock, mutual funds and other similar instruments 22 22 — — Warrants 9 — 9 — Insurance contracts 140 — 140 — Derivative contracts 49 — 49 — Total Assets $ 6,241 $ 6,043 $ 198 $ — Liabilities Derivative contracts $ 68 $ — $ 68 $ — Contingent consideration 44 — — 44 Total Liabilities $ 112 $ — $ 68 $ 44 December 31, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,280 $ 1,280 $ — $ — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 131 — 131 — Derivative contracts 37 — 37 — Total Assets $ 1,473 $ 1,299 $ 174 $ — Liabilities Derivative contracts $ 24 $ — $ 24 $ — Contingent consideration 55 — — 55 Total Liabilities $ 79 $ — $ 24 $ 55
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Contingent Consideration Beginning Balance $ 53 $ 58 $ 55 $ 37 Acquisitions (including assumed balances) — — — 24 Payments (1) (3) (3) (3) Change in fair value included in earnings (8) — (8) (3) Ending Balance $ 44 $ 55 $ 44 $ 55
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. September 26, December 31, (In millions) 2020 2019 Notional Amount Interest rate swaps - fair value hedges (described in Note 7) $ 1,000 $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Cross-currency interest rate swaps 1,000 — Currency exchange contracts 3,893 2,846
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities September 26, December 31, September 26, December 31, (In millions) 2020 2019 2020 2019 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 30 $ — $ — $ 13 Cross-currency interest rate swaps (a) 9 33 5 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 10 4 54 11 Cross-currency interest rate swaps (a) — — 9 — Total Derivatives $ 49 $ 37 $ 68 $ 24 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the consolidated balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability September 26, December 31, September 26, December 31, (In millions) 2020 2019 2020 2019 Long-term Obligations $ 1,024 $ 980 $ 30 $ (13)
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended Nine Months Ended September 26, September 28, September 26, September 28, (In millions) 2020 2019 2020 2019 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ — $ (14) $ (43) $ (95) Derivatives designated as hedging instruments - included in other expense, net — 15 43 98 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (50) (85) (50) Amount reclassified from accumulated other comprehensive items to other expense, net (8) (3) (14) (10) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items (295) 261 (276) 320 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items (30) 72 (30) 79 Included in other expense, net 2 13 9 41 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues (2) 1 (2) — Included in other expense, net 51 43 7 49 Cross-currency interest rate swaps Included in other expense, net 1 — (9) —
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s debt obligations are as follows: September 26, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 21,085 $ 23,415 $ 17,736 $ 18,650 Other 8 8 16 16 $ 21,093 $ 23,423 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s debt obligations are as follows: September 26, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 21,085 $ 23,415 $ 17,736 $ 18,650 Other 8 8 16 16 $ 21,093 $ 23,423 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 26, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended September 26, September 28, (In millions) 2020 2019 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 88 $ 77 Issuance of stock upon vesting of restricted stock units 209 179
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: September 26, December 31, (In millions) 2020 2019 Cash and Cash Equivalents $ 7,540 $ 2,399 Restricted Cash Included in Other Current Assets 29 21 Restricted Cash Included in Other Assets 1 2 Cash, Cash Equivalents and Restricted Cash $ 7,570 $ 2,422

Restructuring and Other Costs_2

Restructuring and Other Costs (Income), Net (Tables)	9 Months Ended
	Sep. 26, 2020
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the third quarter of 2020, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (8) $ 10 $ 2 Analytical Instruments — — 3 3 Specialty Diagnostics — (50) 2 (48) Laboratory Products and Services 1 — 1 2 Corporate — 3 1 4 $ 1 $ (55) $ 17 $ (37) During the first nine months of 2020, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (8) $ 11 $ 3 Analytical Instruments — — 22 22 Specialty Diagnostics — (4) 8 4 Laboratory Products and Services 5 2 20 27 Corporate — 3 6 9 $ 5 $ (7) $ 67 $ 65
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2019 $ 34 Net restructuring charges incurred in 2020 (b) 43 Payments (46) Currency translation 1 Balance at September 26, 2020 $ 32 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Allowance For Doubtful Accounts

Allowance For Doubtful Accounts (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Year	$ 102	$ 117
Provision charged to expense	39	19
Accounts Receivable, Allowance for Credit Loss, Writeoff	(25)	(26)
Acquisitions, currency translation and other		(4)
Balance at End of Period	117	$ 106
Cumulative Effect, Period of Adoption, Adjustment [Member]
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Year	$ 1

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 26, 2020	Sep. 26, 2020	Dec. 31, 2019
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Current Contract Assets, Net	$ 697	$ 697	$ 603
Noncurrent Contract Assets, Net	11	11	17
Current Contract Liabilities	1,047	1,047	916
Noncurrent Contract Liabilities	674	674	$ 594
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 142	$ 773

Warranty Obligations (Details)

Warranty Obligations (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Warranty Obligations [Roll Forward]
Balance at Beginning of Year	$ 93	$ 92
Provision charged to expense	74	80
Usage	(76)	(83)
Adjustments to previously provided warranties, net	(2)	(1)
Currency translation		(2)
Balance at End of Period	$ 89	$ 86

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw Materials	$ 1,247	$ 971
Work in Process	558	517
Finished Goods	2,024	1,882
Inventories	$ 3,829	$ 3,370

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	Sep. 26, 2020	Jan. 01, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances	$ 5,186		$ 4,349
Retained earnings	$ 25,705		$ 22,092
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-13 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances		$ (1)
Retained earnings		$ (1)

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) $ in Millions	1 Months Ended
	Sep. 26, 2020USD ($)
QIAGEN N.V. (Terminated Acquisition) [Member]
Net Assets Acquired [Abstract]
Business Acquisition, Terminated, Reimbursement of Transaction Costs Received	$ 95

Dispositions (Details)

Dispositions (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Jun. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business				$ 0	$ 486
Revenues	$ 8,521	$ 6,272		$ 21,668	18,713
Anatomical Pathology business [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration			$ 1,130
Gain (Loss) on Disposition of Business					$ 482
Revenues			$ 115

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Disaggregation of Revenue [Line Items]
Revenues		$ 8,521	$ 6,272	$ 21,668	$ 18,713
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	4,587	3,220	11,418	9,509
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	2,032	1,514	5,464	4,569
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	1,607	1,349	4,054	4,080
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	295	189	732	555
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues		4,956	3,228	12,214	9,726
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,826	1,570	4,448	4,619
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 1,739	$ 1,474	$ 5,006	$ 4,368
[1]	Revenues are attributed to regions based on customer location.

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Sep. 26, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 11,160
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-09-26
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	72.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Segment Reporting Information [Line Items]
Revenues		$ 8,521	$ 6,272	$ 21,668	$ 18,713
Cost of revenues charges, net		(1)		(5)
Selling, general and administrative credits (charges), net		55		7
Restructuring and other (costs) income, net		(17)	(31)	(67)	442
Amortization of acquisition-related intangible assets				(1,256)	(1,285)
Consolidated operating income		2,426	946	4,723	3,362
Interest Income		9	52	53	179
Interest Expense		(144)	(164)	(407)	(534)
Other (Expense) Income, Net		(39)	(12)	(36)	25
Income before income taxes		2,252	822	4,333	3,032
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative credits (charges), net		8		8
Restructuring and other (costs) income, net		(10)		(11)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other (costs) income, net		(3)		(22)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative credits (charges), net		50		4
Restructuring and other (costs) income, net		(2)		(8)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(1)		(5)
Selling, general and administrative credits (charges), net				(2)
Restructuring and other (costs) income, net		(1)		(20)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Consolidated operating income	[1]	2,803	1,423	6,044	4,275
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		3,424	1,701	7,800	5,018
Consolidated operating income	[1]	1,879	586	3,788	1,756
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		1,336	1,358	3,488	4,004
Consolidated operating income	[1]	171	311	477	879
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		1,430	879	3,376	2,779
Consolidated operating income	[1]	398	223	848	707
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		3,112	2,619	8,629	7,765
Consolidated operating income	[1]	355	303	931	933
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(781)	(285)	(1,625)	(853)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(1)	(5)	(5)	(16)
Selling, general and administrative credits (charges), net		55	(7)	7	(54)
Restructuring and other (costs) income, net		(17)	(31)	(67)	442
Amortization of acquisition-related intangible assets		$ (414)	$ (434)	$ (1,256)	$ (1,285)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles.

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 8,521	$ 6,272	$ 21,668	$ 18,713
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	4,428	3,096	10,981	9,117
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	828	694	1,886	2,072
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 3,265	$ 2,482	$ 8,801	$ 7,524
[1]	Revenues are attributed to countries based on customer location.

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 26, 2020	Jun. 27, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate				21.00%	21.00%
Provision for Income Taxes at Statutory Rate				$ 910	$ 637
Foreign rate differential				(132)	(172)
Foreign exchange loss on inter-company debt refinancing					(62)
Income tax credits				(333)	(242)
Global intangible low-taxed income				210	160
Foreign-derived intangible income				(53)	(68)
Excess tax benefits from stock options and restricted stock units				(94)	(68)
Basis difference on disposal of business					72
Other, net				(52)	81
Provision for Income Taxes	$ 319		$ 62	$ 456	$ 338
US foreign tax credits generated by repatriation of foreign earnings		$ 96

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	9 Months Ended
	Sep. 26, 2020USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at Beginning of Year	$ 1,552
Additions for tax positions of current year	6
Reductions for tax positions of prior years	(38)
Settlements	(7)
Balance at End of Period	$ 1,513

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 1,933	$ 760	$ 3,877	$ 2,694
Basic Weighted Average Shares	396	401	396	400
Effect of Stock Options and Restricted Units	3	3	3	3
Diluted Weighted Average Shares	399	404	399	403
Basic Earnings Per Share (in dollars per share)	$ 4.88	$ 1.89	$ 9.79	$ 6.73
Diluted Earnings Per Share (in dollars per share)	$ 4.84	$ 1.88	$ 9.71	$ 6.68
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	0	1	1	1

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 26, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 21,282	$ 17,960
Fair Value Hedge Accounting Adjustments	30	(13)
Unamortized Discount, Net	(101)	(94)
Unamortized Debt Issuance Costs	(118)	(101)
Total Borrowings at Carrying Value	21,093	17,752
Less: Short-term Obligations and Current Maturities	2	676
Long-term Obligations	21,091	17,076
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 21,085	17,736
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated)
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 7, 2020
Total Borrowings at Par Value		673
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Effective Interest Rate	2.28%
Total Borrowings at Par Value	$ 582	561
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Effective Interest Rate	1.73%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Effective Interest Rate	4.16%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.94%
Total Borrowings at Par Value	$ 1,163	1,121
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.125%
Debt Instrument, Term	5 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2025
Effective Interest Rate	0.41%
Total Borrowings at Par Value	$ 930	897
Senior Notes [Member] | 4.133% 5-Year Senior Notes, Due 3/25/2025
Debt Instrument [Line Items]
Stated Interest Rate	4.133%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Mar. 25, 2025
Effective Interest Rate	4.32%
Total Borrowings at Par Value	$ 1,100
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total Borrowings at Par Value	$ 744	717
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350	350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 814	785
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200	1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.66%
Total Borrowings at Par Value	$ 582	561
Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.75%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2027
Effective Interest Rate	1.97%
Total Borrowings at Par Value	$ 698
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.50%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2028
Effective Interest Rate	0.78%
Total Borrowings at Par Value	$ 930	897
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 698	673
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 814	785
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Stated Interest Rate	2.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Oct. 1, 2029
Effective Interest Rate	2.74%
Total Borrowings at Par Value	$ 900	900
Senior Notes [Member] | 4.497% 10-Year Senior Notes, Due 3/25/2030
Debt Instrument [Line Items]
Stated Interest Rate	4.497%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 25, 2030
Effective Interest Rate	5.31%
Total Borrowings at Par Value	$ 1,100
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.875%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 1, 2031
Effective Interest Rate	1.14%
Total Borrowings at Par Value	$ 1,047	1,009
Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Apr. 15, 2032
Effective Interest Rate	2.55%
Total Borrowings at Par Value	$ 698
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 814	785
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 1, 2039
Effective Interest Rate	1.73%
Total Borrowings at Par Value	$ 1,047	1,009
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400	400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.875%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 1, 2049
Effective Interest Rate	1.99%
Total Borrowings at Par Value	$ 1,163	1,121
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	8	16
Total Borrowings at Carrying Value	$ 8	$ 16

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	9 Months Ended
	Sep. 26, 2020USD ($)
Short-term Financing [Line Items]
Payments of Financing Costs	$ 51,000,000
Expenses Associated with Short-term Financing Commitments	$ 81,000,000
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	5
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA, First and Second Quarter 2021	4
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA, Beginning in the Third Quarter of 2021	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Maximum Borrowing Capacity	$ 2,500,000,000
Letters of Credit Outstanding, Amount	66,000,000
Line of Credit Facility, Amount Outstanding	$ 0
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Debt, Interest Rate Swap Arrang

Debt, Interest Rate Swap Arrangements (Details) - USD ($) $ in Millions		Sep. 26, 2020	Dec. 31, 2019
Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Interest Rate Swap, Pay Rate at Period End		1.92%
Cross Currency Interest Rate Contract [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,000
Interest Rate Swap, Pay Rate at Period End		1.13%
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 900	$ 900
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		1.764%
Interest Rate Swap, Pay Rate at Period End	[1]	1.9164%
Interest Rate Swap, Fixed Receive Rate		3.00%
[1]	The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of September 26, 2020 from 1.92% to a weighted average of 1.13%.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 26, 2020	Jun. 27, 2020
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net	$ 70
Prepayment For Lease, Leases Not Yet Commenced		$ 50
Lessee, Lease Liability Payments Due, Leases Not Yet Commenced	555
Inventories [Member] | Cost of Product Revenues [Member] | Analytical Instruments [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Inventory, Firm Purchase Commitment, Loss	$ 108

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 29,875	$ 28,729	$ 29,675	$ 27,586
Other comprehensive items before reclassifications			(314)
Amounts reclassified from accumulated other comprehensive items			23
Total other comprehensive items	19	(92)	(291)	(224)
Balance	31,824	29,355	31,824	29,355
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(2,320)
Other comprehensive items before reclassifications			(244)
Amounts reclassified from accumulated other comprehensive items			0
Total other comprehensive items			(244)
Balance	(2,564)		(2,564)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(71)
Other comprehensive items before reclassifications			(65)
Amounts reclassified from accumulated other comprehensive items			10
Total other comprehensive items			(55)
Balance	(126)		(126)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(288)
Other comprehensive items before reclassifications			(5)
Amounts reclassified from accumulated other comprehensive items			13
Total other comprehensive items			8
Balance	(280)		(280)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,989)	(2,630)	(2,679)	(2,498)
Total other comprehensive items	19	(92)	(291)	(224)
Balance	$ (2,970)	$ (2,722)	$ (2,970)	$ (2,722)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Assets [Abstract]
Cash equivalents	$ 6,021	$ 1,280
Investments in common stock, mutual funds and other similar instruments	22	19
Warrants	9	6
Insurance contracts	140	131
Derivative contracts	49	37
Total Assets	6,241	1,473
Liabilities [Abstract]
Derivative contracts	68	24
Contingent consideration	44	55
Total Liabilities	112	79
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	6,021	1,280
Investments in common stock, mutual funds and other similar instruments	22	19
Total Assets	6,043	1,299
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	9	6
Insurance contracts	140	131
Derivative contracts	49	37
Total Assets	198	174
Liabilities [Abstract]
Derivative contracts	68	24
Total Liabilities	68	24
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	44	55
Total Liabilities	$ 44	$ 55

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 53	$ 58	$ 55	$ 37
Acquisitions (including assumed balances)				24
Payments	(1)	(3)	(3)	(3)
Change in fair value included in earnings	(8)		(8)	(3)
Ending Balance	$ 44	$ 55	$ 44	$ 55
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]			us-gaap:SellingGeneralAndAdministrativeExpense

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	$ 30	$ (13)
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge	1,024	980
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	30	(13)
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	30
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities		13
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,000	1,000
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,000
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	9	33
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	5
Cross Currency Interest Rate Contract [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	9
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	3,893	2,846
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	10	4
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	54	11
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	49	37
Derivative Liabilities	$ 68	$ 24

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019
Cross Currency Interest Rate Contract [Member] | Other Expense, Net [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 1		$ (9)
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(2)	$ 1	(2)
Currency Exchange Contracts [Member] | Other Expense, Net [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	51	43	7	$ 49
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Hedged long-term obligations in Fair Value Hedge		(14)	(43)	(95)
Gain (Loss) on Derivative, Net		15	43	98
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in OCI on Cash Flow Hedge		(50)	(85)	(50)
Payments for Hedge, Financing Activities			85
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Reclassified from AOCI	(8)	(3)	(14)	(10)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	(295)	261	(276)	320
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	(30)	72	(30)	79
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 2	$ 13	$ 9	$ 41

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Sep. 26, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ 23,423	$ 18,666
Long-term Debt	21,093	17,752
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	23,415	18,650
Long-term Debt	21,085	17,736
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	8	16
Long-term Debt	$ 8	$ 16

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 26, 2020	Sep. 28, 2019	Dec. 31, 2019	Dec. 31, 2018
Non-cash Investing and Financing Activities [Abstract]
Declared but unpaid dividends	$ 88	$ 77
Issuance of stock upon vesting of restricted stock units	209	179
Cash and Cash Equivalents	7,540		$ 2,399
Restricted Cash Included in Other Current Assets	29		21
Restricted Cash Included in Other Assets	1		2
Cash, Cash Equivalents and Restricted Cash	$ 7,570	$ 1,305	$ 2,422	$ 2,117
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent

Restructuring and Other Costs_3

Restructuring and Other Costs (Income), Net (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 26, 2020	Sep. 28, 2019	Sep. 26, 2020	Sep. 28, 2019	Oct. 30, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated less than				1.00%
Cost of Revenues		$ 1		$ 5
Selling, General and Administrative Expenses		(55)		(7)
Restructuring and other costs (income), net		17	$ 31	67	$ (442)
Total Restructuring and Other Costs (Income), Net		(37)		65
Restructuring and Related Costs, Cash Costs	[1],[2]			43
Restructuring and Related Costs, Other Costs (Income), Net				24
Loss (Gain) on Divestiture of Businesses				0	$ (486)
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		(8)		(8)
Restructuring and other costs (income), net		10		11
Total Restructuring and Other Costs (Income), Net		2		3
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs (income), net		3		22
Total Restructuring and Other Costs (Income), Net		3		22
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		(50)		(4)
Restructuring and other costs (income), net		2		8
Total Restructuring and Other Costs (Income), Net		(48)		4
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		1		5
Selling, General and Administrative Expenses				2
Restructuring and other costs (income), net		1		20
Total Restructuring and Other Costs (Income), Net		2		27
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		3		3
Restructuring and other costs (income), net		1		6
Total Restructuring and Other Costs (Income), Net		$ 4		$ 9
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs						$ 45
[1]	Excludes $24 million of charges for impairment of acquired technology in development, fixed asset writedowns and costs associated with environmental remediation at abandoned / previously owned facilities.
[2]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	9 Months Ended
	Sep. 26, 2020USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 34	[1]
Costs incurred	43	[1],[2]
Payments	(46)	[1]
Currency translation	1	[1]
Ending balance	32	[1]
Restructuring and Related Costs, Other Costs (Income), Net	$ 24
Restructuring Reserve, Expected Final Year of Payments	2021
[1]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
[2]	Excludes $24 million of charges for impairment of acquired technology in development, fixed asset writedowns and costs associated with environmental remediation at abandoned / previously owned facilities.